Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MTMQA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
M-1231
|
|||||
| Synonyms |
M 1231; M-1231; M1231
Click to Show/Hide
|
|||||
| Organization |
EMD Serono Research & Development Institute, Inc.; The University of Texas MD Anderson Cancer Center; Sutro Biopharma, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
A antibody scaffold targeting tumor-associated MUC1 and EGFR
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
SC209
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
DBCO-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Puchem SID | ||||||
